Legence (LGN) stock drops nearly 9% today as contractors slide ahead of U.S. payrolls

Legence (LGN) stock drops nearly 9% today as contractors slide ahead of U.S. payrolls

New York, Jan 8, 2026, 14:38 EST — Regular session

  • Legence shares slid about 9% in afternoon trading, reversing an early move higher
  • Contractor peers also fell, while Wall Street traded mixed ahead of key U.S. jobs data
  • Traders are watching Friday’s payrolls report and any further deal-related filings from Legence

Legence Corp (LGN.O) shares fell about 9% to $43.99 on Thursday, after earlier touching $48.79. The stock closed at $48.32 on Wednesday.

The pullback lands on a newly public name that has moved fast since its September debut. Blackstone-backed Legence raised $728 million in an IPO priced at $28 a share and sells engineering and maintenance work for building systems, including heating and air conditioning. 1

Broader markets offered little shelter. Wall Street was mixed on Thursday and traders focused on Friday’s nonfarm payrolls report for December, with technology shares weighing on the Nasdaq. 2

Other construction and engineering stocks were also lower: Comfort Systems USA was down about 7%, EMCOR about 5% and Quanta Services about 6%. Legence traded as low as $43.67 and volume topped 600,000 shares.

The company’s last major update came on Jan. 2, when it said it completed its acquisition of The Bowers Group, paying $325 million in cash and issuing about 2.55 million shares. Chief Executive Jeff Sprau called it “an important milestone in our growth strategy.” 3

A regulatory filing showed Legence funded the cash portion with a mix that included a $200 million incremental term loan facility that it drew in full at closing. A term loan is long-term borrowing; the company said the incremental loans carry terms identical to its existing term debt and it expects to file deal financials and pro forma information within 71 days. 4

At its last quarterly report in November, Legence forecast 2026 revenue of $2.65 billion to $2.85 billion and adjusted EBITDA of $295 million to $315 million. Adjusted EBITDA is a non-GAAP profit gauge that backs out items like interest, taxes and depreciation to give a cleaner view of operating performance. 5

Thursday’s slide also took the shares back below $45, the price used in an upsized secondary offering by selling stockholders in December. The prospectus said Legence did not sell any shares in that deal and would not receive proceeds, and it warned that future stock sales could pressure the share price. 6

But big swings cut both ways for a fresh IPO with an acquisition and new borrowing in the mix. A hotter-than-expected jobs report could keep rate worries alive, and any stumble in integrating recent deals could hit margins.

Stock Market Today

Seatrium stock slips to S$2.06 — what to watch after an AmFELS date fix and ahead of results

7 February 2026
Singapore, Feb 7, 2026, 15:28 SGT — Market closed Seatrium Ltd shares closed down nearly 1% on Friday, leaving the Singapore-listed offshore and marine group heading into the weekend on a soft note after a run of company updates earlier in the week. 1 The move matters now because Seatrium has two narratives running at once: asset reshaping, including the US yard exit, and a growing slate of offshore wind work that has become a bigger swing factor for workload and execution risk. It also comes with a tighter spotlight on disclosures and timing. The company corrected a key date
Hongkong Land share price drops 4% despite fresh buyback — what investors watch next

Hongkong Land share price drops 4% despite fresh buyback — what investors watch next

7 February 2026
Hongkong Land shares fell 4.2% to US$8.18 in Singapore on Friday after the company disclosed a buyback of 170,000 shares at US$8.5252 each on Feb. 5, with plans to cancel them. The drop followed a volatile week marked by a new Singapore real estate fund launch and an expanded buyback programme. Investors are watching for the group’s annual results on March 5.
Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens
Previous Story

Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

Carpenter Technology stock slides as investors size up Jan. 29 earnings catalyst
Next Story

Carpenter Technology stock slides as investors size up Jan. 29 earnings catalyst

Go toTop